FDA Panel Pans OTC Singulair Proposal

Fri, 05/02/2014 - 4:39pm
The Associated Press

Federal health advisers have voted against a Merck proposal to sell its prescription respiratory pill Singulair as an over-the-counter allergy medication.

The Food and Drug Administration's panel of experts voted 11-4 Friday against making the drug available without a prescription. Merck sells Singulair via prescription for asthma and allergies.

Singulair was once Merck's best-selling drug, but sales have plummeted since the drug's patent expired in mid-2012, exposing the brand to low cost generics.

Merck & Co. Inc. hopes to revive sales of the former blockbuster as an over-the-counter allergy medication.

But FDA's advisers said the safety of Singulair as an over-the-counter treatment has not been established, particularly since patients could use it off-label for more serious conditions like asthma.

The FDA is not required to follow the expert panel's vote.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.